Kyverna Therapeutics, Inc. KYTX Operating lease liabilities
Operating lease liabilities at other companies
Other financials
Where this comes from
Reported directly by Kyverna Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInOperatingLeaseLiability.
The official record: Kyverna Therapeutics, Inc.’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →
Ask your AI about Kyverna Therapeutics, Inc.'s operating lease liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Kyverna Therapeutics, Inc.'s operating lease liabilities?
- Kyverna Therapeutics, Inc. (KYTX) reported operating lease liabilities of -$503K in Q1 2026.
- How has Kyverna Therapeutics, Inc.'s operating lease liabilities changed year-over-year?
- Kyverna Therapeutics, Inc.'s operating lease liabilities increased by 47.8% year-over-year, from -$963K to -$503K.
- What is the long-term trend for Kyverna Therapeutics, Inc.'s operating lease liabilities?
- Over 2 years (2023 to 2025), Kyverna Therapeutics, Inc.'s operating lease liabilities has grown at a 41.0% compound annual growth rate (CAGR), from -$1.68M to -$3.34M.